Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Wed, 11.11.2020
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 11, 2020
MorphoSys Reports Nine Months and Third Quarter
2020 Results
Conference call and webcast (in English) to be held on November 12, 2020 at 2:00pm CET (1:00pm GMT/8:00am EST)
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reports results for the first nine mon [ … ]
Wed, 11.11.2020
MorphoSys AG
Media Release
Planegg/Munich/Würzburg, Germany, November 11, 2020
MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
- The parties signed a multi-target exclusive licensing agreement for application of Cherry Biolabs' Hemibody technology
- Combination with MorphoSys' antibody know-how enables discovery and development of [ … ]
Wed, 11.11.2020
MorphoSys AG
Media Release
Monrovia, California, U.S.; Planegg/Munich, Germany; and Wilmington, Delaware, U.S., November 11, 2020
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incy [ … ]
Wed, 04.11.2020
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 4, 2020
MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that multiple abstracts regarding the company's proprietary key asset tafasitamab have been accepted for [ … ]
Wed, 04.11.2020
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 4, 2020
Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its results for the third quarter and first 9-month of 2020 on November 11, 2020 [ … ]
Tue, 27.10.2020
MorphoSys AG
Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany, October 27, 2020
Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announces today an increase in its financial guidance for the financial year 2020 after preliminary c [ … ]
Mon, 19.10.2020
MorphoSys AG
MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
PLANEGG/MUNICH, Germany, October 19, 2020 - MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Researc [ … ]
Tue, 13.10.2020
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR AUSTRALIA, SOUTH AFRICA, JAPAN OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW
Planegg/Munich, Germany, October 13, 2020
MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
Mo [ … ]
Tue, 13.10.2020
MorphoSys AG
Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany, October 13, 2020
Ad hoc: MorphoSys AG Launches an Offering of approx.EUR 325 Million Convertible Bonds
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announces to launch an offering of unsubordinated, unsecured convertible bonds d [ … ]
Wed, 30.09.2020
MorphoSys AG
MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020
PLANEGG/MUNICH, Germany, September 30, 2020 - MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and one of the leaders in antibody, protein and peptide technologies, today announced that Jens Holstein, C [ … ]